Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility

• Published in: World journal of transplantation 2016-12, Vol.6 (4), p.759-766
• Main Authors: Vlachopanos, Georgios, Bridson, Julie M, Sharma, Ajay, Halawa, Ahmed
• Format: Article
• Language: English
• Subjects: Evidence-Based Medicine
• ISSN: 2220-3230; 2220-3230
• DOI: 10.5500/wjt.v6.i4.759

To explore the benefits and harms of corticosteroid (CS) minimization following renal transplantation. CS minimization attempts to improve cardiovascular risk factors (hypertension, diabetes, dyslipidemia), to enhance growth in children, to ameliorate bone disease and to lead to better compliance with immunosuppressive agents. Nevertheless, any benefit must be carefully weighed against the reduction in net immunosuppression and the potential harm to renal allograft function and survival. Complete CS avoidance or very early withdrawal ( ., no CS after post-transplant day 7) seems to be associated with better outcomes in comparison with later withdrawal. However, an increased incidence of CS-sensitive acute rejection has been observed with all CS minimization strategies. Among the prerequisites for the safe application of CS minimization protocols are the administration of induction immunosuppression and the inclusion of calcineurin inhibitors in maintenance immunosuppression regimens. Transplant recipients at low immunological risk (primary transplant, low panel reactive antibodies) are thought as optimal candidates for CS minimization. CS avoidance may also be undesirable in patients at risk for glomerulonephritis recurrence or with severe delayed graft function and prolonged cold ischemia time. Thus, CS minimization is not yet ready for implementation in the majority of transplant recipients.